Protein Folding And Calcium Binding Defects Account For Errors In Familial Hypercholesterolemia

August 30, 1996

Familial hypercholesterolemia, a genetic disease characterized by high levels of cholesterol and early mortality, is caused by defects in the receptor for the low-density lipoprotein (LDL)
All proteins are strings of amino acids that must fold into a unique shape to perform their function. 3Knowing that a protein folding defect is at the root of familial hypercholesterolemia may allow scientists to design better therapies. It could allow one to screen for drugs or identify therapies that enable the defective receptor to fold properly,2 says Dr. Peter Kim of the Whitehead Institute for Biomedical Research and the Howard Hughes Medical Institute (HHMI). He and colleague Dr. Stephen Blacklow of the Whitehead Institue, Brigham and Women1s Hospital and HHMI report their findings in the September issue of Nature Structural Biology.

Protein folding defects have also been implicated in other human diseases, including cystic fibrosis, a-1-antitrypsin deficiency, retinitis pigmentosa, and Marfan1s syndrome. 3Our studies provide yet another example of how basic science research, such as studies of protein folding, ultimately help us understand human disease,2 says Dr. Kim.

Normally, cholesterol is removed from the bloodstream and taken into cells by the LDL receptor on the cell surface. Scientists have known that a defective LDL receptor results in high levels of blood cholesterol. In most cases of familial hypercholesterolemia, this happens because the gene for the LDL receptor is slightly mutated.

In the Whitehead-HHMI study, researchers studied a critical fragment of the LDL receptor that frequently contains single amino acid mutations in patients with

familial hypercholesterolemia. 3We found that the normal copy of this crucial fragment folds into its proper shape, but introducing even single mutations in the fragment interferes with the fragment1s ability to fold into this shape,2 says Dr. Blacklow. Combining nuclear magnetic resonance (NMR) spectroscopy and other biochemical methods, researchers also found that the normal copy of this fragment was unable to fold properly in the absence of calcium, and adding calcium restored its folding ability. Based on these data and other biochemical information, researchers speculate that the mutations in the LDL receptor affect the receptor1s ability to bind calcium and therefore its ability to fold into its proper shape.

This work was funded in part by the National Heart, Lung and Blood Institute.


Background

Familial hypercholesterolemia (FH) is an autosomal dominant trait, meaning that a child born to an affected parent has a 50 percent chance of inheriting the gene. About 1 in 500 people are heterozygous for FH
In the 1970s, Drs. Michael Brown and Joseph Goldstein discovered that LDL is removed from the bloodstream by receptors on the cell surface and that these receptors are mutated in familial hypercholesterolemia. The new understanding of the role of these cellular receptors in regulating cholesterol levels in the bloodstream spurred the successful treatment strategy for high cholesterol using a combination of drugs and diet change to lower blood cholesterol levels. Drs. Goldstein and Brown were awarded the 1985 Nobel Prize for Medicine or Physiology for their work.

Whitehead Institute for Biomedical Research

Related Cholesterol Articles from Brightsurf:

Cholesterol's effects on cellular membranes
The findings have far-reaching implications in the general understanding of disease, the design of drug delivery methods, and many other biological applications that require specific assumptions about the role of cholesterol in cell membranes.

Autism-cholesterol link
Study identifies genetic link between cholesterol alterations and autism.

Microbes might manage your cholesterol
Researchers discover a link between human blood cholesterol levels and a gene in the microbiome that could one day help people manage their cholesterol through diet, probiotics, or entirely new types of treatment.

Experimental cholesterol-lowering drug effective at lowering bad cholesterol, study shows
Twice-yearly injections of an experimental cholesterol-lowering drug, inclisiran, were effective at reducing low-density lipoprotein (LDL) cholesterol, often called bad cholesterol, in patients already taking the maximum dose of statin drugs, according to data of the ORION-10 trial presented Saturday, Nov.

Rethinking how cholesterol is integrated into cells
Cholesterol is best known in connection with cardiovascular disease, but cholesterol is also vital for many fundamental processes in the body.

Seed oils are best for LDL cholesterol
Using a statistical technique called network meta-analysis, researchers have combined the results of dozens of studies of dietary oils to identify those with the best effect on patients' LDL cholesterol and other blood lipids.

Cholesterol leash: Key tethering protein found to transport cellular cholesterol
Cholesterol is an essential component of living organisms, but the mechanisms that transport cholesterol inside the cell are poorly understood.

New way to treat cholesterol may be on the horizon
A breakthrough discovery by scientists at Houston Methodist Research Institute could change the way we treat cholesterol.

How low should LDL cholesterol go?
New analysis shows that in a high-risk population, achieving ultra-low LDL cholesterol levels, down to <10 mg/dL, safely results in additional lowering of risk of cardiovascular events.

Does boosting 'good' cholesterol really improve your health?
A new review addresses the mysteries behind 'good' HDL cholesterol and why boosting its levels does not necessarily provide protection from cardiovascular risk for patients.

Read More: Cholesterol News and Cholesterol Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.